Understand your risk. Make informed decisions. Advocate for yourself. Support the research.
Scientific | Medical Advisors and Contributors
Professor Parry Guilford, MSc, PhD
Director, University of Otago, Center for Translational Cancer Research, Dunedin NZParry has been working on HDGC since 1995, when he teamed up with a New Zealand Māori family to try and uncover the cause of stomach cancer running through several Māori communities. Following the identification of CDH1’s role in 1998, his research group in the Cancer Genetics Laboratory, University of Otago, moved on to studying how CDH1 mutations lead to cancer. Over the last five years, the focus has shifted to the development of drugs which can be used to prevent and treat diffuse gastric cancer and lobular breast cancer in HDGC families.
Dr. Guilford’s Profile
Johanna D'Addario, MHS, PA-C
Physician Assistant, Gynecologic Oncology, Yale-New Haven Health, New Haven CTJohanna D’Addario is a CDH1 mutation carrier and breast cancer survivor living in Connecticut. She was diagnosed with a CDH1 mutation in 2008, had a preventative total gastrectomy in 2010 at the age of 26, and a bilateral mastectomy in 2015 at age 31. She is passionate about connecting with and supporting others who have had similar challenges in life. She works as a physician assistant in women’s oncology services and cares for women who are at high risk of gynecologic cancers. She tries to honor her father Greg, who died of Hereditary Diffuse Gastric Cancer in 2009, by living each day to its fullest.
Johanna lives with her husband Tom and their dog, Cooper, and enjoys traveling, exercise, the theater, and spending time with friends and family.